TORONTO - Canada's Drug Agency is recommending that public drug plans pay for a treatment shown to slow the progression of early-stage Alzheimer's disease if patients meet certain conditions.
TORONTO - Canada’s Drug Agency is recommending that public drug plans pay for a treatment shown to slow the progression of early-stage Alzheimer’s disease if patients meet certain conditions.
Lecanemab is an antibody that targets the buildup of amyloid plaque in the brain, which is believed to be an underlying cause of the disease.
Subcutaneous, intravenous outcomes with lecanemab comparable in Alzheimer’s disease
FDA approves Leqembi Iqlik® (lecanemab-irmb) subcutaneous injection as a starting dose for early Alzheimer's disease
Subcutaneous Leqembi approved for initiation; long-term stability with treatment indicated
Los neurólogos piden a Sanidad que no se niegue a financiar los fármacos para el alzhéimer precoz
An experimental Alzheimer's drug shows some promise as researchers hunt new approaches
New experimental Alzheimer's drug shows potential after study shows slower cognitive decline | Fortune
New experimental drug shows promise in slowing early Alzheimer’s
Experimental Alzheimer's drug shows some promise as researchers hunt new approaches
FDA Approves LEQEMBI IQLIK® (lecanemab-irmb) Subcutaneous Injection as an Initiation Dose for Early Alzheimer's Disease
More than 75% of Leqembi®-treated patients remained stable and nearly 7% improved over an average of 17 months of treatment in real-world LEADER study data presented at AAIC® 2026
Canada recently approved lecanemab to treat early Alzheimer's disease, but the clinical benefits are modest, it carries a risk of…
Das neue Alzheimer-Medikament Lecanemab kann den Verlauf der Krankheit im Frühstadium um einige Monate verzögern. Seit dem 1.…
Die EU hat Donanemab als neue Alzheimer-Therapie zugelassen, nach dem Mittel Lecanemab. Beide Medikamente zielen auf…
Das neue Alzheimer-Medikament Lecanemab kann den Verlauf der Krankheit im Frühstadium um einige Monate verzögern. Seit dem 1.…
Lecanemab soll bei Alzheimer im Frühstadium helfen. Doch längst nicht alle Patienten profitieren. Die Therapie ist teuer – und…
Outcomes following subcutaneous and intravenous treatment with lecanemab for Alzheimer’s disease were comparable, according to a…
